THE DISTRIBUTION OF FV-LEIDEN, PROTHROMBIN AND PLASMINOGEN ACTIVATOR INHIBITOR GENE MUTATIONS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA

Basit Öğe Kaydı
dc.contributor.authorBalbay, Ege Güleç
dc.contributor.authorKüçük, Enes
dc.contributor.authorBalbay, O.
dc.contributor.authorAnnakkaya, Ali Nihat
dc.contributor.authorSılan, Fatma
dc.contributor.authorÇiçekliyurt, Meliha Merve
dc.date.accessioned2020-04-30T23:32:47Z
dc.date.available2020-04-30T23:32:47Z
dc.date.issued2014
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionBalbay, Ege Gulec/0000-0002-1557-7019; Annakkaya, Ali Nihat N/0000-0002-7661-8830en_US
dc.descriptionWOS: 000337197500011en_US
dc.description.abstractAim: To investigate Factor V Leiden (FVL), Plasminogen Activator Inhibitor (PAI) or Prothrombin (F2L) gene polymorphisms among OSAS patients. Methods: 62 patients (35 male, 27 female) with the suspected diagnosis of OSAS were included. All patients filled out a questionnaire regarding sleep disturbance and underwent polysomnographic (PSG) examination. Genotypes were determined by a polymerase chain reaction and reverse hybridization. Results: The mean age was 51 +/- 12. 20 of the patients were not OSAS while 42 was OSAS. The distribution of FVL genotypes for 1691 GG, GA and AA is found 95 %, 5% and 0% in control group and 88.1%, 11.9% and 0% in patient groups (p:0.654) respectively. The mutant genotype was not observed for both FVL and F2L G20210A. The distribution of F2L 2021 GG, GA, AA was found 95%, 5% and 0% in control group while 97.6%, 2.4% and 0% in patient group (p:0.545) respectively. The genotype frequencies of the OSAS patients for PAT were 45.5% for wild, 45% for heterozygote, and 10% for homozygote mutant genotype in control group and 31% for wild, 47.6% for heterozygote, and 21.4% for homozygote mutant genotype in patient group (p:0.413). No significant associations with these three polymorphism were observed for OSAS and the data was shown as odds value for FVL, F2L respectively; ORFVL=2.5 (95% CI: 0.280-23.573), ORF2L =0.463 (95% CI: 0.027-7.811). Conclusion: Although FVL mutation was insignificantly high in OSAS patients, it may be an important risk factor in known hypercoagulabi-en_US
dc.identifier.endpage70en_US
dc.identifier.issn1015-8146
dc.identifier.issue1en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage69en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4815
dc.identifier.volume25en_US
dc.identifier.wosWOS:000337197500011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMedecine Et Hygieneen_US
dc.relation.ispartofGenetic Counselingen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleTHE DISTRIBUTION OF FV-LEIDEN, PROTHROMBIN AND PLASMINOGEN ACTIVATOR INHIBITOR GENE MUTATIONS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEAen_US
dc.typeLetteren_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
4815.PDF
Boyut:
137.45 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Diğer Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu